TY - JOUR
T1 - Beyond conventional chemotherapy
T2 - Emerging molecular targeted and immunotherapy strategies in urothelial carcinoma
AU - Ikeda, Sadakatsu
AU - Hansel, Donna E.
AU - Kurzrock, Razelle
N1 - Funding Information:
Funded in part by the Joan and Irwin Jacobs Fund and My Answer to Cancer philanthropic fund .
Publisher Copyright:
© 2015 The Authors.
PY - 2015/9/1
Y1 - 2015/9/1
N2 - Advanced urothelial carcinoma is frequently lethal, and improvements in cytotoxic chemotherapy have plateaued. Recent technological advances allows for a comprehensive analysis of genomic alterations in a timely manner. The Cancer Genome Atlas (TCGA) study revealed that there are numerous genomic aberrations in muscle-invasive urothelial carcinoma, such as TP53, ARID1A, PIK3CA, ERCC2, FGFR3, and HER2. Molecular targeted therapies against similar genetic alterations are currently available for other malignancies, but their efficacy in urothelial carcinoma has not been established. This review describes the genomic landscape of malignant urothelial carcinomas, with an emphasis on the potential to prosecute these tumours by deploying novel targeted agents and immunotherapy in appropriately selected patient populations.
AB - Advanced urothelial carcinoma is frequently lethal, and improvements in cytotoxic chemotherapy have plateaued. Recent technological advances allows for a comprehensive analysis of genomic alterations in a timely manner. The Cancer Genome Atlas (TCGA) study revealed that there are numerous genomic aberrations in muscle-invasive urothelial carcinoma, such as TP53, ARID1A, PIK3CA, ERCC2, FGFR3, and HER2. Molecular targeted therapies against similar genetic alterations are currently available for other malignancies, but their efficacy in urothelial carcinoma has not been established. This review describes the genomic landscape of malignant urothelial carcinomas, with an emphasis on the potential to prosecute these tumours by deploying novel targeted agents and immunotherapy in appropriately selected patient populations.
KW - Genetic aberrations
KW - Immune therapy
KW - Targeted therapy
KW - Urothelial carcinoma
UR - http://www.scopus.com/inward/record.url?scp=84941023230&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84941023230&partnerID=8YFLogxK
U2 - 10.1016/j.ctrv.2015.06.004
DO - 10.1016/j.ctrv.2015.06.004
M3 - Review article
C2 - 26138514
AN - SCOPUS:84941023230
SN - 0305-7372
VL - 41
SP - 699
EP - 706
JO - Cancer Treatment Reviews
JF - Cancer Treatment Reviews
IS - 8
ER -